Tarextumab

Tarextumab (formerly OMP-59R5) is a fully human monoclonal antibody targeting the Notch 2/3 receptors. It is being tested as a possible treatment for cancer. In Jan 2015 the US FDA granted orphan drug designation to tarextumab for the treatment of pancreatic cancer and lung cancer. Two early stage clinical trials have reported encouraging results.

Contents

• Dr o reilly on tarextumab combinations for metastatic pancreatic cancer
• Tarextumab in combination with nab paclitaxel and gemcitabine in pancreatic cancer
• References